NVS's Wise Choice: Avoiding GLP-1 Diet Pills Trend
The GLP-1 weight-loss drug market is massive, but the competition is fierce. Instead of joining the race, Swiss pharma giant $Novartis AG(NVS)$ is playing it smart, focusing on more strategic growth areas.
Novartis is sticking to what it’s good at
CEO Vas Narasimhan recently said in an interview that the company has no plans to jump into the "crazy" weight-loss market, claiming they’ve got better options. He’s aiming to invest in projects with bigger potential payoffs, like radioligand cancer therapies, which could bring in up to $20 billion.
Novartis is also eyeing other opportunities in treatments for Parkinson's, Huntington's, and Alzheimer’s diseases. Compared to the ultra-competitive weight-loss field, these areas might offer more solid ground for the company. Trying to carve out a spot in the weight-loss market would be risky and might not pay off.
Bypassing the GLP-1 hype keeps Novartis' valuation reasonable
In recent years, a surefire way for healthcare companies to boost their stock price has been to dive into the weight-loss market. Even if they don’t have an approved GLP-1 product yet, just showing positive trial results can send stock prices soaring.
But since Novartis hasn’t jumped on the weight-loss bandwagon, even though its stock has risen 15% this year, it's still lagging behind the S&P 500’s 22% gain. On the upside, this keeps Novartis' valuation in check. Its forward price-to-earnings ratio is 14, compared to the healthcare sector’s average of 22 in the Health Care Select Sector SPDR Fund.
Because of this more measured growth strategy, Novartis might actually be an undervalued growth stock. The company projects a steady 5% annual sales increase through 2027—nothing spectacular, but solid. Plus, it avoids the sky-high market expectations that could lead to disappointment.
Novartis is ideal for growth-focused, risk-averse investors
If you're looking for a stock with decent growth potential but lower risk, Novartis is a solid bet. The management’s strategy is careful and realistic, meaning there’s a good chance they’ll exceed expectations.
Plus, the stock currently boasts a 3.3% dividend yield—more than double the $.SPX(.SPX)$ 's average of 1.3%—making it a strong option for long-term investors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
